Home > Journals > Minerva Biotechnology and Biomolecular Research > Past Issues > Minerva Biotecnologica 2020 December;32(4) > Minerva Biotecnologica 2020 December;32(4):188-94

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Minerva Biotecnologica 2020 December;32(4):188-94

DOI: 10.23736/S1120-4826.20.02681-6

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Performance of cytokeratin-18 apoptotic fragment for the identification of hepatic fibrosis and inflammation in patients with chronic viral hepatitis: a meta-analysis

Chiara ROSSO 1 , Gian P. CAVIGLIA 1, Angelo ARMANDI 1, Maria L. ABATE 1, Antonella OLIVERO 1, Davide G. RIBALDONE 1, 2, Rinaldo PELLICANO 2, Giorgio M. SARACCO 1, 2, Elisabetta BUGIANESI 1, 2

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Division of Gastroenterology, Molinette Hospital, Città della Salute e della Scienza, Turin, Italy



INTRODUCTION: The search for non-invasive tools aiming to assess liver fibrosis and inflammation, and able to replace liver biopsy, remains one of the most important unmet need in clinical practice. Although cytokeratin 18-Asp396 (CK18-Asp396) apoptotic fragment has been considered an important marker of hepatitis progression, until now, conflicting results have been reported. Therefore, we performed a meta-analysis to evaluate the diagnostic accuracy of CK18-Asp396 for the detection of fibrosis and inflammation in patients with chronic hepatitis C (CHC) and chronic hepatitis B (CHB) infection.
EVIDENCE ACQUISITION: Through PubMed and Scopus databases, we identified published papers on the evaluation of the diagnostic performance of CK18-Asp396 for the discrimination of patients with significant fibrosis and inflammation. Statistical analysis was performed with MedCalc Software.
EVIDENCE SYNTHESIS: A total of 11 studies (425 patients with CHC and 1012 patients with CHB infection) were included in the meta-analysis. The median cut-off value of CK18-Asp396 marker for the identification of significant fibrosis was higher compared to the median cut-off value for the discrimination of significant inflammation (294 U/L vs. 234 U/L, P=0.05). The weighted summary area under the curve (sAUC) of CK18-Asp396 for the detection of significant fibrosis and inflammation was 0.75 (95% confidence interval [CI]=0.66-0.83) and 0.75 (95% CI=0.70-0.79), respectively. No difference was observed between the diagnostic performance of CK18-Asp396 in identifying significant fibrosis and significant inflammation.
CONCLUSIONS: The measurement of serum CK18-Asp396 showed a moderate diagnostic accuracy for the detection of both significant fibrosis and significant inflammation in patients with chronic viral hepatitis. Possibly, the combination of CK18-Asp396 with other biomarkers of disease severity may improve its diagnostic performance.


KEY WORDS: Viral hepatitis; Meta-analysis; Hepatitis

top of page